TD Cowen Maintains Buy on Standard BioTools, Lowers Price Target to $2.75
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Daniel Brennan maintains a Buy rating on Standard BioTools (NASDAQ:LAB) but lowers the price target from $3.5 to $2.75.

August 01, 2024 | 6:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TD Cowen analyst Daniel Brennan maintains a Buy rating on Standard BioTools but lowers the price target from $3.5 to $2.75.
The Buy rating suggests continued confidence in the stock, but the lowered price target indicates a more cautious outlook on its short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100